Investors might want to bet on Nuvation Bio Inc. (NUVB), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...

Nuvation Bio Inc. (NYSE:NUVB) is one of the 10 best healthcare penny stocks to buy according to analysts. JMP Securities ...

Nuvation Bio, listed via SPAC in 2021, and acquired AnHeart Therapeutics last year, gaining taletrectinib, a promising ROS1 inhibitor indicated for non-small cell lung cancer.

Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer ...

The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's drug for patients with a rare and aggressive form of lung cancer.

Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer ...

NEW YORK, August 05, 2024--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today reported financial ...

Nuvation therefore believed “it would be difficult to craft an effective mitigation plan without significant further research.” Related Top 10 game-changing biotech layoffs in H1 ...

Nuvation Bio's IBTROZI received FDA approval for ROS1+ NSCLC, but the stock dropped sharply due to mandated costly post-marketing trials and high SG&A expenses.

Insiders were net buyers of Nuvation Bio Inc.'s (NYSE:NUVB ) stock during the past year. That is, insiders bought more stock than they sold. While we would never suggest that investors should base ...